3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
15
Cisplatin
7
Cetuximab
5
dostarlimab
3
Surveys and Questionnaires
3
Carboplatin
3
fludarabine
2
abemaciclib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Nivolumab
2
Interviews as Topic
2
Fulvestrant
2
Docetaxel
2
Cyclophosphamide
2
Blood Specimen Collection
2
130-nm albumin-bound paclitaxel
2
ulixertinib
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
ribociclib
1
repotrectinib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
nimotuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
STX-478
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled